T. Rowe Price Associates
DMAC icon

T. Rowe Price Associates’s DiaMedica Therapeutics DMAC Stock Holding History

T. Rowe Price Associates’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Buy
23,170
+3,510
+18% +$27.8K ﹤0.01% 2902
2025
Q4 		$157K Hold
19,660
– – ﹤0.01% 2865
2025
Q3 		$136K Buy
19,660
+6,292
+47% +$34.1K ﹤0.01% 2870
2025
Q2 		$53K Buy
+13,368
New +$52.1K ﹤0.01% 2997

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's DMAC Position: Q1 2026 in Review

T. Rowe Price Associates increased its DiaMedica Therapeutics (DMAC) stake by 18% in Q1 2026, buying an estimated $27.8K and bringing the position to 23,170 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #2902.

T. Rowe Price Associates first reported a position in DMAC in Q2 2025 and has held it in 4 quarters since. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • T. Rowe Price Associates held 23,170 shares of DiaMedica Therapeutics worth $157K as of Q1 2026.
  • T. Rowe Price Associates bought 3,510 DiaMedica Therapeutics shares in Q1 2026, an estimated $27.8K.
  • DiaMedica Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2902 holding.
  • T. Rowe Price Associates first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.